STOCK TITAN

Hologic (HOLX) director exits position as merger pays $76 plus CVRs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hologic, Inc. director Christiana Stamoulis reported the cash-out of her equity in connection with a merger. All reported holdings, including 50,526 shares of common stock and several non-qualified stock option grants, were disposed of to the issuer, leaving her with no remaining Hologic equity.

Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that may pay up to an additional $3.00 in cash per share.

Positive

  • None.

Negative

  • None.
Insider Stamoulis Christiana
Role Director
Type Security Shares Price Value
Disposition Non-qualified Stock Option (Right to Buy) 6,816 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 7,551 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 6,523 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 7,322 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,055 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,293 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 4,210 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 4,536 $0.00 --
Disposition Non-qualified Stock Option (Right to Buy) 5,535 $0.00 --
Disposition Common Stock 50,526 $0.00 --
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 0 shares (Direct)
Footnotes (1)
  1. Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. For Footnote (3), see Remarks below.
Merger cash consideration $76.00 per share Cash paid for each share of Hologic common stock at the merger
Contingent value right up to $3.00 per share Potential additional cash per share via CVR under merger terms
Common shares disposed 50,526 shares Hologic common stock surrendered to issuer in merger by reporting person
Option grant 1 strike price $41.92 per share Non-qualified stock option on 6,816 underlying shares disposed to issuer
Option grant 2 strike price $38.44 per share Non-qualified stock option on 7,551 underlying shares disposed to issuer
Latest option grant strike $64.36 per share Non-qualified stock option on 5,535 underlying shares disposed to issuer
Dispose transactions 10 transactions All reported as dispositions to issuer on the same transaction date
Post-transaction holdings 0 shares/options Total shares and options reported as remaining after merger-related dispositions
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025…"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"."
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
contingent value right financial
"one (1) contingent value right, which represents the right to receive up to $3.00 in cash…"
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
Non-qualified Stock Option (Right to Buy) financial
"security_title": "Non-qualified Stock Option (Right to Buy)""
restricted stock unit award financial
"each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person…"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stamoulis Christiana

(Last)(First)(Middle)
250 CAMPUS DRIVE

(Street)
MARLBOROUGH MASSACHUSETTS 01752

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/07/2026D50,526D(1)(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$41.9204/07/2026D6,816 (3)03/08/2027Common Stock6,816(3)0D
Non-qualified Stock Option (Right to Buy)$38.4404/07/2026D7,551 (3)03/14/2028Common Stock7,551(3)0D
Non-qualified Stock Option (Right to Buy)$46.8104/07/2026D6,523 (3)03/07/2029Common Stock6,523(3)0D
Non-qualified Stock Option (Right to Buy)$47.3604/07/2026D7,322 (3)03/05/2030Common Stock7,322(3)0D
Non-qualified Stock Option (Right to Buy)$71.0304/07/2026D5,055 (3)03/11/2031Common Stock5,055(3)0D
Non-qualified Stock Option (Right to Buy)$70.2804/07/2026D5,293 (3)03/10/2032Common Stock5,293(3)0D
Non-qualified Stock Option (Right to Buy)$78.4904/07/2026D4,210 (3)03/09/2033Common Stock4,210(3)0D
Non-qualified Stock Option (Right to Buy)$76.3204/07/2026D4,536 (3)03/07/2034Common Stock4,536(3)0D
Non-qualified Stock Option (Right to Buy)$64.3604/07/2026D5,535 (3)02/26/2035Common Stock5,535(3)0D
Explanation of Responses:
1. Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
2. At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
3. For Footnote (3), see Remarks below.
Remarks:
(3) Pursuant to the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (a "Company Option") with an exercise price per share less than the Cash Consideration was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (A) the number of shares of Company Common Stock subject to such Company Option, multiplied by (B) the excess of the Cash Consideration over the exercise price per share of the Company Option, and (ii) one CVR with respect to each share. Each outstanding Company Option with an exercise price per share equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and $3.00 was cancelled and converted into the right to receive one CVR with respect to each share of Company Common Stock subject to such Company Option, payment in respect of which will be net of the excess of the applicable exercise price per share of the Company Option over $76.00. Each outstanding Company Option with an exercise price per share of Company Common Stock equal to or greater than the sum of the Cash Consideration and $3.00 was cancelled for no consideration.
/s/ Mark W. Irving, attorney-in-fact for Ms. Stamoulis04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Christiana Stamoulis report at HOLOGIC INC (HOLX)?

Christiana Stamoulis reported disposing of all her Hologic equity in an issuer-related transaction. This included 50,526 shares of common stock and multiple non-qualified stock option awards, all cancelled or surrendered in connection with a merger, leaving her with no remaining beneficial ownership.

How many HOLOGIC INC (HOLX) common shares were affected in this Form 4?

The Form 4 shows 50,526 shares of Hologic common stock disposed of to the issuer. These shares were converted at the merger’s effective time into the right to receive cash consideration plus contingent value rights, eliminating the reporting person’s direct or indirect common stock holdings.

What were the terms of the HOLOGIC INC (HOLX) merger consideration per share?

Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right. Each contingent value right may provide up to an additional $3.00 in cash per share, depending on future conditions specified in the merger documentation.

What happened to Christiana Stamoulis’s HOLOGIC INC (HOLX) stock options?

Several non-qualified stock option awards held by Christiana Stamoulis, covering thousands of Hologic shares at exercise prices such as $41.92, $38.44 and $71.03, were disposed of to the issuer at the merger’s effective time, resulting in zero remaining option holdings after the transaction.

Does Christiana Stamoulis still own HOLOGIC INC (HOLX) shares after the merger?

According to the filing, she no longer beneficially owns any Hologic common stock. Her time-vesting restricted stock units and all reported common shares were converted into rights to receive the merger consideration, so her direct and indirect ownership position in Hologic common stock is now zero.

What is a contingent value right (CVR) in the HOLOGIC INC (HOLX) merger?

In this merger, each share of Hologic common stock received one contingent value right. Each CVR represents the right to receive up to $3.00 in additional cash per share, if specified future conditions are met, providing potential extra value beyond the $76.00 cash payment.